Published in Genomics on May 17, 2012
Gigwa-Genotype investigator for genome-wide analyses. Gigascience (2016) 1.07
Exposome informatics: considerations for the design of future biomedical research information systems. J Am Med Inform Assoc (2013) 1.07
Big data and biomedical informatics: a challenging opportunity. Yearb Med Inform (2014) 1.02
Open source libraries and frameworks for biological data visualisation: a guide for developers. Proteomics (2015) 1.00
targetHub: a programmable interface for miRNA-gene interactions. Bioinformatics (2013) 0.81
BigQ: a NoSQL based framework to handle genomic variants in i2b2. BMC Bioinformatics (2015) 0.77
Big Data: the challenge for small research groups in the era of cancer genomics. Br J Cancer (2015) 0.77
RefPrimeCouch--a reference gene primer CouchApp. Database (Oxford) (2013) 0.75
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res (2002) 76.95
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
The International HapMap Project. Nature (2003) 73.65
From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res (2006) 44.35
The distributed annotation system. BMC Bioinformatics (2001) 42.98
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 39.25
miRBase: tools for microRNA genomics. Nucleic Acids Res (2007) 38.61
The microRNA Registry. Nucleic Acids Res (2004) 29.45
miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res (2010) 25.85
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
The UCSC Genome Browser database: update 2011. Nucleic Acids Res (2010) 16.24
DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res (2006) 15.19
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res (2007) 13.94
DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res (2010) 13.68
BioMart--biological queries made easy. BMC Genomics (2009) 11.06
STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res (2005) 10.44
Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res (2010) 9.09
BioMart Central Portal--unified access to biological data. Nucleic Acids Res (2009) 9.06
The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res (2005) 7.81
The RCSB Protein Data Bank: redesigned web site and web services. Nucleic Acids Res (2010) 7.68
Integrating biological data--the Distributed Annotation System. BMC Bioinformatics (2008) 6.56
GeneCards Version 3: the human gene integrator. Database (Oxford) (2010) 6.05
The International HapMap Project Web site. Genome Res (2005) 5.96
TTD: Therapeutic Target Database. Nucleic Acids Res (2002) 4.91
STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res (2007) 4.88
Medical Subject Headings (MeSH). Bull Med Libr Assoc (2000) 4.44
SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res (2007) 3.82
STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res (2009) 3.06
A relational model of data for large shared data banks. 1970. MD Comput (1998) 2.94
Update of TTD: Therapeutic Target Database. Nucleic Acids Res (2009) 2.35
PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics (2008) 2.35
SeqWare Query Engine: storing and searching sequence data in the cloud. BMC Bioinformatics (2010) 1.72
GeneDecks: paralog hunting and gene-set distillation with GeneCards annotation. OMICS (2009) 1.51
SuperLigands - a database of ligand structures derived from the Protein Data Bank. BMC Bioinformatics (2005) 1.28
Knowledge engineering tools for reasoning with scientific observations and interpretations: a neural connectivity use case. BMC Bioinformatics (2011) 1.12
Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res (2008) 1.11
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (2004) 4.58
Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics (2005) 4.26
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Focus on lung cancer. Cancer Cell (2002) 3.41
Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst (2005) 3.31
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg (2004) 2.62
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Microarrays: retracing steps. Nat Med (2007) 2.39
Breast lymphoma: imaging findings of 32 tumors in 27 patients. Radiology (2007) 2.31
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 2.22
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg (2004) 2.18
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17
Malignant pleural mesothelioma. J Clin Oncol (2009) 2.16
Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg (2013) 2.15
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res (2009) 2.11
The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief Funct Genomic Proteomic (2005) 2.08
Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer (2005) 2.04
Applications of beta-mixture models in bioinformatics. Bioinformatics (2005) 2.04
Treatment outcomes of resected esophageal cancer. Ann Surg (2002) 2.03
A Semantic Web management model for integrative biomedical informatics. PLoS One (2008) 2.02
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications. Ann Thorac Surg (2007) 2.01
Bayesian analysis of mass spectrometry proteomic data using wavelet-based functional mixed models. Biometrics (2007) 2.01
A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics (2003) 2.01
The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform (2009) 1.98
Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J Clin Oncol (2008) 1.96
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther (2009) 1.86
Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg (2007) 1.79
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics (2002) 1.75
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood (2009) 1.75
Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg (2005) 1.72
Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol (2012) 1.71
Variable slope normalization of reverse phase protein arrays. Bioinformatics (2009) 1.66
Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol (2006) 1.64
Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg (2002) 1.64
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer (2006) 1.63
Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res (2002) 1.61
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59
Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst (2007) 1.58
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg (2007) 1.54
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One (2009) 1.53
Enrichment analysis in high-throughput genomics - accounting for dependency in the NULL. Brief Bioinform (2006) 1.52
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52
The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg (2012) 1.51
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One (2011) 1.51
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood (2006) 1.49
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood (2009) 1.47
The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol (2006) 1.46
Analysis of mass spectrometry profiles of the serum proteome. Clin Chem (2005) 1.46
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys (2003) 1.45
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res (2005) 1.45
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol (2004) 1.43
Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood (2010) 1.43
3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol (2005) 1.42
Development of Ad-mda7/IL-24-resistant lung cancer cell lines. Cancer Biol Ther (2007) 1.42
Increased risk of aspiration and pulmonary complications after lung resection in head and neck cancer patients. Ann Thorac Surg (2006) 1.42
Activating enhancer-binding protein-2β nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann Thorac Surg (2011) 1.41
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer (2005) 1.40
Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. Biotechniques (2005) 1.39
A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res (2007) 1.39
miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck (2009) 1.38
Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res (2010) 1.38
Non-small cell lung cancer resection in lymphoma patients. Ann Thorac Surg (2010) 1.38
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer (2009) 1.36
Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem (2002) 1.35
Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood (2011) 1.34
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res (2003) 1.32
Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther (2004) 1.32
Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano (2012) 1.30
Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res (2010) 1.30
Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res (2007) 1.29
Bayesian shrinkage estimation of the relative abundance of mRNA transcripts using SAGE. Biometrics (2003) 1.28
Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res (2008) 1.28
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood (2003) 1.28